In oncology patients who undergo positron emission tomography (PET)/computed tomography (CT), radiolabeled [18F]-2-fluoro-2-deoxy-D-glucose (FDG) is utilized to obtain qualitative and quantitative data about tumour metabolism. The process of patient preparation before FDG-PET/CT imaging (scanning) primarily includes acquisition of patient data, fasting before imaging, regulation of blood glucose and insulin levels, administration of FDG and radiologic contrast material, administration of adjunctive…
Read more...